| Original language | English |
|---|---|
| Title of host publication | The Encyclopaedia of Pharmacy Practice and Clinical Pharmacy |
| Editors | Zaheer-Ud-Din Babar |
| Place of Publication | San Diego |
| Publisher | Elsevier Science Publishing Co Inc |
| Chapter | 509 |
| Pages | 264-281 |
| Number of pages | 18 |
| Edition | 1st |
| ISBN (Electronic) | 9780128127360 |
| ISBN (Print) | 9780128127353 |
| DOIs | |
| Publication status | Published - 20 Jun 2019 |
Abstract
Chronic obstructive pulmonary disease (COPD) is a preventable and treatable chronic lung disease characterized by persistent respiratory symptoms and airflow limitation. It is caused mainly by chronic exposure to inhaled irritants, especially through tobacco smoking. COPD is projected to be the 3rd leading cause of death by 2020. More than 3 million people died of COPD in 2012 accounting for 6% of all deaths globally. Exacerbations are a major cause of morbidity and mortality in patients with COPD, with adverse effects on quality of life and lung function. Pharmacists have a key role to play in the prevention, diagnosis, and management of the disease and symptoms. Short-acting and long-acting bronchodilators (beta agonists, muscarinic antagonists) alone or in combination, antiinflammatory agents (oral and inhaled corticosteroids), mucolytics and antibiotics (as required) are central to COPD management. Vaccination (influenza and pneumococcal), pulmonary rehabilitation and patient self-management guided by action plans may reduce the burden of COPD. Pharmacists can be actively involved in delivering smoking cessation interventions, case-finding of COPD (i.e., screening of high risk people with symptoms) using symptom questionnaires and handheld devices, and rationalize COPD management in both primary and secondary care settings by optimizing medicine use by both prescribers and patients.
Keywords
- Bronchodilator
- Chronic obstructive pulmonary disease
- COPD
- Dyspnea
- Exacerbation
- Inflammation
- Mucus hypersecretion
- Pharmacist
- Pharmacy
- Public health
- Pulmonary rehabilitation
- Self-management
- Smoking
- Spirometry
Cite this
George, J., & Liang, J. (2019). Management of respiratory disorders and the pharmacist's role: COPD. In Z-U-D. Babar (Ed.), The Encyclopaedia of Pharmacy Practice and Clinical Pharmacy (1st ed., pp. 264-281). San Diego: Elsevier Science Publishing Co Inc. https://doi.org/10.1016/B978-0-12-812735-3.00509-4
@inbook{bbdeb08daf5d4effb508e94bdf440344,
title = "Management of respiratory disorders and the pharmacist's role: COPD",
abstract = "Chronic obstructive pulmonary disease (COPD) is a preventable and treatable chronic lung disease characterized by persistent respiratory symptoms and airflow limitation. It is caused mainly by chronic exposure to inhaled irritants, especially through tobacco smoking. COPD is projected to be the 3rd leading cause of death by 2020. More than 3 million people died of COPD in 2012 accounting for 6{\%} of all deaths globally. Exacerbations are a major cause of morbidity and mortality in patients with COPD, with adverse effects on quality of life and lung function. Pharmacists have a key role to play in the prevention, diagnosis, and management of the disease and symptoms. Short-acting and long-acting bronchodilators (beta agonists, muscarinic antagonists) alone or in combination, antiinflammatory agents (oral and inhaled corticosteroids), mucolytics and antibiotics (as required) are central to COPD management. Vaccination (influenza and pneumococcal), pulmonary rehabilitation and patient self-management guided by action plans may reduce the burden of COPD. Pharmacists can be actively involved in delivering smoking cessation interventions, case-finding of COPD (i.e., screening of high risk people with symptoms) using symptom questionnaires and handheld devices, and rationalize COPD management in both primary and secondary care settings by optimizing medicine use by both prescribers and patients.",
keywords = "Bronchodilator, Chronic obstructive pulmonary disease, COPD, Dyspnea, Exacerbation, Inflammation, Mucus hypersecretion, Pharmacist, Pharmacy, Public health, Pulmonary rehabilitation, Self-management, Smoking, Spirometry",
author = "Johnson George and Jenifer Liang",
year = "2019",
month = "6",
day = "20",
doi = "10.1016/B978-0-12-812735-3.00509-4",
language = "English",
isbn = "9780128127353",
pages = "264--281",
editor = "Zaheer-Ud-Din Babar",
booktitle = "The Encyclopaedia of Pharmacy Practice and Clinical Pharmacy",
publisher = "Elsevier Science Publishing Co Inc",
edition = "1st",
}
George, J & Liang, J 2019, Management of respiratory disorders and the pharmacist's role: COPD. in Z-U-D Babar (ed.), The Encyclopaedia of Pharmacy Practice and Clinical Pharmacy. 1st edn, Elsevier Science Publishing Co Inc, San Diego, pp. 264-281. https://doi.org/10.1016/B978-0-12-812735-3.00509-4
Management of respiratory disorders and the pharmacist's role : COPD. / George, Johnson; Liang, Jenifer.
The Encyclopaedia of Pharmacy Practice and Clinical Pharmacy. ed. / Zaheer-Ud-Din Babar. 1st. ed. San Diego : Elsevier Science Publishing Co Inc, 2019. p. 264-281.Research output: Chapter in Book/Report/Conference proceeding › Encyclopaedia / Dictionary Entry › Other › peer-review
TY - CHAP
T1 - Management of respiratory disorders and the pharmacist's role
T2 - COPD
AU - George, Johnson
AU - Liang, Jenifer
PY - 2019/6/20
Y1 - 2019/6/20
N2 - Chronic obstructive pulmonary disease (COPD) is a preventable and treatable chronic lung disease characterized by persistent respiratory symptoms and airflow limitation. It is caused mainly by chronic exposure to inhaled irritants, especially through tobacco smoking. COPD is projected to be the 3rd leading cause of death by 2020. More than 3 million people died of COPD in 2012 accounting for 6% of all deaths globally. Exacerbations are a major cause of morbidity and mortality in patients with COPD, with adverse effects on quality of life and lung function. Pharmacists have a key role to play in the prevention, diagnosis, and management of the disease and symptoms. Short-acting and long-acting bronchodilators (beta agonists, muscarinic antagonists) alone or in combination, antiinflammatory agents (oral and inhaled corticosteroids), mucolytics and antibiotics (as required) are central to COPD management. Vaccination (influenza and pneumococcal), pulmonary rehabilitation and patient self-management guided by action plans may reduce the burden of COPD. Pharmacists can be actively involved in delivering smoking cessation interventions, case-finding of COPD (i.e., screening of high risk people with symptoms) using symptom questionnaires and handheld devices, and rationalize COPD management in both primary and secondary care settings by optimizing medicine use by both prescribers and patients.
AB - Chronic obstructive pulmonary disease (COPD) is a preventable and treatable chronic lung disease characterized by persistent respiratory symptoms and airflow limitation. It is caused mainly by chronic exposure to inhaled irritants, especially through tobacco smoking. COPD is projected to be the 3rd leading cause of death by 2020. More than 3 million people died of COPD in 2012 accounting for 6% of all deaths globally. Exacerbations are a major cause of morbidity and mortality in patients with COPD, with adverse effects on quality of life and lung function. Pharmacists have a key role to play in the prevention, diagnosis, and management of the disease and symptoms. Short-acting and long-acting bronchodilators (beta agonists, muscarinic antagonists) alone or in combination, antiinflammatory agents (oral and inhaled corticosteroids), mucolytics and antibiotics (as required) are central to COPD management. Vaccination (influenza and pneumococcal), pulmonary rehabilitation and patient self-management guided by action plans may reduce the burden of COPD. Pharmacists can be actively involved in delivering smoking cessation interventions, case-finding of COPD (i.e., screening of high risk people with symptoms) using symptom questionnaires and handheld devices, and rationalize COPD management in both primary and secondary care settings by optimizing medicine use by both prescribers and patients.
KW - Bronchodilator
KW - Chronic obstructive pulmonary disease
KW - COPD
KW - Dyspnea
KW - Exacerbation
KW - Inflammation
KW - Mucus hypersecretion
KW - Pharmacist
KW - Pharmacy
KW - Public health
KW - Pulmonary rehabilitation
KW - Self-management
KW - Smoking
KW - Spirometry
U2 - 10.1016/B978-0-12-812735-3.00509-4
DO - 10.1016/B978-0-12-812735-3.00509-4
M3 - Encyclopaedia / Dictionary Entry
SN - 9780128127353
SP - 264
EP - 281
BT - The Encyclopaedia of Pharmacy Practice and Clinical Pharmacy
A2 - Babar, Zaheer-Ud-Din
PB - Elsevier Science Publishing Co Inc
CY - San Diego
ER -
George J, Liang J. Management of respiratory disorders and the pharmacist's role: COPD. In Babar Z-U-D, editor, The Encyclopaedia of Pharmacy Practice and Clinical Pharmacy. 1st ed. San Diego: Elsevier Science Publishing Co Inc. 2019. p. 264-281 https://doi.org/10.1016/B978-0-12-812735-3.00509-4